Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study

Published:2014-12-15 Issue:1 Volume:115 Page:65-73
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Joly Florence¹²,Delva Remy³,Mourey Loïc⁴,Sevin Emmanuel¹,Bompas Emmanuelle⁵,Vedrine Lionel⁶,Ravaud Alain⁷,Eymard Jean-Christophe⁸,Tubiana-Mathieu Nicole⁹,Linassier Claude¹⁰,Houede Nadine¹¹,Guillot Aline¹²,Ringensen François¹³,Cojocarasu Oana¹⁴,Valenza Bruno¹⁵,Leconte Alexandra²,Lheureux Stéphanie¹,Clarisse Bénédicte²,Oudard Stéphane¹⁶

Affiliation:

1. Medical Oncology-Clinical Research Department; Centre François Baclesse - CHU Côte de Nacre; Caen France

2. Universite Basse Normandie; Caen France

3. Medical Oncology; Institut de Cancérologie de l'Ouest Centre Paul Papin; Angers France

4. Medical Oncology; Institut Claudius Régaud; Toulouse France

5. Oncology; Centre René Gauducheau; Nantes France

6. Medical Oncology; Hôpital du Val de Grâce; Paris France

7. Medical Oncology; Hôpital Saint-André; Bordeaux France

8. Medical Oncology; Institut Jean Godinot; Reims France

9. Medical Oncology; Hôpital Dupuytren; Limoges France

10. Medical Oncology; Hôpital Bretonneau; Tours France

11. Medical Oncology; Institut Bergonié; Bordeaux France

12. Institut de Cancérologie de la Loire; Saint-Etienne France

13. Medical Oncology; Centre Hospitalier Universitaire; Grenoble France

14. Medical Oncology; Centre Hospitalier; Le Mans France

15. Oncology-Hematology; Centre Hospitalier; Frejus France

16. Medical Oncology Department; Georges Pompidou Hospital; Paris France

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.12552/fullpdf

Reference26 articles.

1. Early androgen deprivation for prostate cancer?;Eisenberger;N Engl J Med,1999

2. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer;Tannock;N Engl J Med,2004

3. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer;Petrylak;N Engl J Med,2004

4. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study;Eymard;BJU Int,2010

5. Management of advanced prostate cancer after first-line chemotherapy;Berthold;J Clin Oncol,2005

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Geriatric evaluation methods in oncology and their use in clinical studies: A systematic literature review;Journal of Geriatric Oncology;2023-12

2. Phosphodiesterase Type 5 Inhibitors Synergize Vincristine in Killing Castration-Resistant Prostate Cancer Through Amplifying Mitotic Arrest Signaling;Frontiers in Oncology;2020-08-07

3. Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.;Cancer Treatment and Research Communications;2020

4. Efficacy and safety of post-docetaxel therapies in metastatic castration-resistant prostate cancer: a systematic review of the literature;Current Medical Research and Opinion;2017-07-10

5. Patient experience in the treatment of metastatic castration-resistant prostate cancer: state of the science;Prostate Cancer and Prostatic Diseases;2016-02-02

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3